Moreover, our work implied that EPHA2 and PDGFRA might be therapeutic targets for GBM with high expression of both proteins, emphasizing that the molecular mechanisms underlying PDGFA signaling activation by new binding partners need to be clarified in detail for application of PDGFA-related therapeutic strategies on GBM treatment. The gene discussed is EPHA2; the disease is glioblastoma.